Industry News

OncBioMune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being hosted at the..."/>
OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, announces that its President, Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, has accepted an invitation to speak at Harvard Medical School this November. Dabney will speak at the Dana Farber/Harvard Cancer Center, one of the largest cancer research centers in the world with more than 1,100 cancer researchers and over $600 million in cancer..."/>
Mr. Raymond C. Dabney, CBIS CEO, Accepts Invitation to Speak at Harvard Medical School
Baxter Among Top 100 of More than 5,000 Publicly Traded Companies. DEERFIELD, Ill.---- Baxter International Inc. has been recognized by Thomson Reuters as a Top 100 company for outstanding practices in diversity and inclusion in its inaugural Diversity& Inclusion Index, which debuted today. The index and ratings are designed to transparently and objectively measure the relative performance of companies against factors that define..."/>
Baxter Ranked as One of the Most Diverse and Inclusive Workplaces Globally by Thomson Reuters
Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, today announced that it has agreed to acquire PharmaCore Inc., a privately-owned company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000 sq. ft. GMP site in High Point, North Carolina, USA.."/>
Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc., a leading, global functional service provider serving the biopharmaceutical industry. The acquisition is expected to close in the next three weeks. Terms of the transaction were not disclosed."/>
PAREXEL Announces Execution Of Definitive Agreement To Acquire ExecuPharm; Acquisition will strengthen and add scale to current functional services offering to meet growing demand
Repros Therapeutics to participate as a Sponsor-- developing a therapy specifically designed to treat secondary hypogonadism. THE WOODLANDS, Texas, Sept. 26, 2016-- Repros Therapeutics Inc. ® today noted that it will participate as a sponsor in a forthcoming public advisory committee meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee recently announced by the Food and Drug Administration. The general function of the committee is to provide advice and..."/>
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
American Renal Associates Holdings, Inc. during the period April 20, 2016 through August 18, 2016. Esposito v. American Renal Associates Holdings, Inc., et al.. The securities fraud lawsuit charges that during the Class Period, ARA, in order to obtain higher reimbursement rates, conspired to..."/>
Wolf Popper LLP Updates Status of Investigation on Behalf of Investors in Pending Securities Fraud Class Action against American Renal Associations Holdings, Inc., and Reminds Investors of Upcoming Lead Plaintiff Deadline
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has acquired exclusive, worldwide rights from Eli Lilly and Company to develop and commercialize LY3130418. CERC-611 is a potent and selective Transmembrane AMPA Receptor Regulatory Proteins-..."/>
Cerecor Announces Acquisition of TARP-?8-AMPA Receptor Antagonist (CERC-611) from Lilly
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that its lead antibody development program, HuMab 5 B1, was featured in three separate presentations at the recently held World Molecular Imaging Congress in September. The presentations were made by investigators from the Department of Radiology at Memorial Sloan Kettering Cancer Center describing the novel use of MabVax's lead antibody..."/>
MabVax Therapeutics HuMab-5B1 Based Diagnostic Imaging and Radioimmunotherapy Programs Featured at the 2016 World Molecular Imaging Congress
Quorum Health Corporation between April 29, 2016 and August 10, 2016, inclusive, and/or pursuant or traceable to Quorum’ s false and misleading Registration Statement issued in connection with the Company’ s spinoff from Community Health Systems effective on or about April..."/>
QHC INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Quorum Health Corporation
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc., a leading, global functional service provider serving the biopharmaceutical industry. The acquisition is expected to close in the next three weeks."/>
PAREXEL Announces Execution of Definitive Agreement to Acquire ExecuPharm
Varian Medical Systems as the immobilization device for its HyperArc High Definition Radiotherapy solution. The prescribed frameless Qfix Encompass SRS Immobilization System restricts the movement of the patient and allows patient positioning with sub-millimeter accuracy to..."/>
Qfix® Encompass™ SRS Immobilization System is now validated and cleared for use with HyperArc™ High Definition Radiotherapy treatment delivery
AirXpanders Inc., a company developing a novel technology for women undergoing tissue expansion for breast reconstruction following a mastectomy, today announced that new data on the use of its AeroForm ® Tissue Expander System was presented at the American Society of Plastic Surgeons Plastic Surgery: The Meeting 2016 in Los Angeles. Currently under review with FDA, AeroForm is a needle-free, patient-controlled tissue expander..."/>
Positive Results from Use of AirXpanders' AeroForm® Tissue Expander System Highlighted at ASPS Annual Meeting
AbbVie, a global biopharmaceutical company, today announced that new data on HUMIRA ® and investigational medicine risankizumab, an IL-23 inhibitor, will be presented at the 25 th European Academy of Dermatology and Venereology Congress, September 28- October 2, in Vienna, Austria. These presentations build upon AbbVie's continued scientific leadership in serious dermatological conditions including psoriasis, psoriatic..."/>
AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it has entered into a definitive agreement with institutional investors to purchase shares of common stock for aggregate gross proceeds of approximately $930,000 in a registered direct offering. The closing of the offering is expected to take place on or about September 29, 2016, subject to the..."/>
BioPharmX Announces Registered Direct Offering
Mast Therapeutics, Inc. today provided an update related to its business strategy and the clinical development of its product candidates. The Company's cash, cash equivalents, and investment securities were $30.3 million at August 31, 2016. The Company will focus on clinical development of AIR001 for the treatment of heart failure with preserved ejection fraction. Specifically, during 2016 and 2017, the Company will continue to support..."/>
Mast Therapeutics Provides Business Update
Tonix Pharmaceuticals Holding Corp., which is developing a next-generation treatment for posttraumatic stress disorder, announced today that it will present at the 16th Annual Biotech in Europe Forum being held on September 27-28, 2016 in Basel, Switzerland by Sachs Associates.. Ronald Notvest, Ph.D., Executive Vice President, Commercial Planning and Development at Tonix, will provide a corporate update and an overview of Tonix’ s PTSD clinical program."/>
Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
Roche launches low-cost PT/INR home monitoring app
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has been awarded a grant from the United States Department of Agriculture to develop a POC diagnostic test for bovine tuberculosis. The $600,000 grant is managed by the Small Business Innovation Research Program of the National Institute of Food and Agriculture, a federal agency within the USDA.. Under the two-year grant,..."/>
Chembio Awarded Grant from U.S. Department of Agriculture to Develop Point-of-Care Diagnostic Test for Bovine Tuberculosis
WellCare Health Plans, Inc. announced today it appointed Anat Hakim to senior vice president, general counsel and secretary, effective September 26. Hakim will be responsible for leading the company's legal department. She will report to WellCare's CEO Ken Burdick."/>
WellCare Appoints Anat Hakim to Senior Vice President, General Counsel and Secretary
Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting a corporate overview during the meeting’ s Partnering Forum on Wednesday, October 5, 2016, at 5:15 pm PDT. The conference will be held October 5-7 at the Estancia La Jolla Hotel& Spa in La Jolla California..."/>
Histogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced recent progress in its clinical programs with MIN-101 for schizophrenia and with MIN-117 for major depressive..."/>
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
Cumberland Pharmaceuticals Inc., announced today that it has launched the U.S. promotion of Ethyol ® for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated..."/>
Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient Support

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology589 Articles
Consumer Discretionary545 Articles
Financials358 Articles
Industrials336 Articles
Health Care328 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at